Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...
Nobody has ever contracted HIV or hepatitis from toilet roll, as the viruses don't survive for long outside the body.
A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than ...
In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...
Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...
Gilead’s twice-yearly injection for HIV prevention cut infections by 96% in a late-stage trial, the company said Thursday, ...
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96% compared to an expected rate ...
HIV stigma, for the first time in five years, is on the decline in the United States, despite knowledge gaps in certain ...
Researchers have shown unprecedented control of SIV replication and decay of viral reservoirs by combining a stringent model of infection with the interruption of antiretroviral therapy (ART). The ...